Brain Malignancies Steering Committee

The NCI Brain Malignancies Steering Committee (BMSC) was established in November 2010. It addresses the design, prioritization, and evaluation of concepts for large phase 2 and phase 3 clinical trials in adult brain cancers and all pediatric brain cancer trials. View the BMSC roster as of November 04, 2024.

Strategic Priorities

• BMSC Strategic Priorities were formulated with the goal that the majority of submitted concepts would align with these established priorities. They address areas of unmet clinical need, important unanswered clinical questions, and potential new approaches to disease treatment.

Clinical Trials Planning Meetings (CTPMs)

CTPMs are held periodically and focus on specific clinical trial related topics. The following are important BMSC CTPMs:

• Improving the Treatment of Glioblastoma
  Held in September 2013, this one and a half day meeting was designed to translate advances in both immunotherapy and targeted therapies into concepts for clinical trials in glioblastoma. Read the executive summary and 2014 publication, Report from the Targeted Therapies Working Group - Neuro-Oncology.

Contact

For more information, contact NCI CCCT Program Director, Abdul Tawab Amiri, Ph.D., at atawab@mail.nih.gov.